CMA Recommendations on Vaccine Equity and Intellectual Property
https://policybase.cma.ca/link/policy14476

POLICY TYPE
Parliamentary submission

DATE
2022-05-13

TOPICS
Ethics and medical professionalism
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents

CMA Recommendations on Vaccine Equity and Intellectual Property
House of Commons Standing Committee on Foreign Affairs and International Development
May 11, 2022

CMA Policybase - Canadian Medical Association
Appearance before the Standing Committee on Human Resources, Skills and Social Development and the Status of Persons with Disabilities
https://policybase.cma.ca/link/policy14472

POLICY TYPE  Parliamentary submission
DATE  2022-03-28
TOPICS  Health human resources
Health systems, system funding and performance

Documents

Appearance before the
Standing Committee on Human
Resources, Skills and Social
Development and the Status of
Persons with Disabilities

Dr. Kathleen Smart,
President of the Canadian Medical Association
March 28, 2022

[Image credit: Canadian Medical Association]
Federal Policy Options to Advance Pan-Canadian Licensure
https://policybase.cma.ca/link/policy4471

POLICY TYPE
Parliamentary submission

DATE
2022-02-22

TOPICS
Health systems, system funding and performance
Health human resources
Ethics and medical professionalism

Documents

Federal Policy Options to Advance Pan-Canadian Licensure

Improving health care by reducing interprovincial and interterritorial barriers
February 22, 2022

CMA submission
Study on Canada’s Health Workforce

https://policybase.cma.ca/link/policy14469

POLICY TYPE  Parliamentary submission
DATE  2022-02-16
TOPICS  Health systems, system funding and performance
         Health human resources
         Ethics and medical professionalism

Documents

Appearance before the House of Commons Standing Committee on Health:

Study on Canada’s Health Workforce

Dr. Corky Kelly
President of the Canadian Medical Association
February 16, 2022
Direct support services
<table>
<thead>
<tr>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health systems, system funding and performance</td>
</tr>
<tr>
<td>Health human resources</td>
</tr>
<tr>
<td>Ethics and medical professionalism</td>
</tr>
</tbody>
</table>

**Recommendations for federal action to address Canada’s health care crisis**

https://policybase.cma.ca/link/policy14468

**POLICY TYPE**  Parliamentary submission

**DATE**  2022-02-15

**TOPICS**

- Health systems, system funding and performance
- Health human resources
- Ethics and medical professionalism
Mandatory COVID-19 vaccination of health care workers

Policy document

DATE
2021-08-21

TOPICS
Health human resources
Population health, health equity, public health

Documents

https://policybase.cma.ca/link/policy14443

POLICY TYPE
Policy endorsement

DATE
2021-06-24

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Consensus statement on networks for high-quality rural anesthesia, surgery, and obstetric care in Canada
https://policybase.cma.ca/link/policy14477

POLICY TYPE: Policy endorsement
DATE: 2021-05-17
TOPICS: Health systems, system funding and performance, Health human resources

Documents
Valuing Caregivers and Recognizing Their Contribution to Quebec’s Health System
https://policybase.cma.ca/link/policy14373

POLICY TYPE  Parliamentary submission
DATE  2020-09-29
TOPICS  Health human resources
         Health systems, system funding and performance

Documents

[Image of document cover]
Taking action on drug shortages during Covid-19 – open letter
https://policybase.cma.ca/link/policy14261

POLICY TYPE
Parliamentary submission

DATE
2020-08-13

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

Dear Health Minister,

We are writing to you today to alert you to a specific situation and issue in the healthcare system in Canada that is causing significant harm to patients, providers, and the healthcare system. As we are all aware, the COVID-19 pandemic has created unprecedented challenges for healthcare systems around the world. In Canada, we have seen a surge in demand for certain medications, particularly those related to COVID-19 treatment.

The situation is particularly concerning for patients who rely on specific medications. In some cases, there have been shortages of certain drugs, leading to difficulties in obtaining necessary medications for treatment. This is not only impacting patients with chronic conditions but also those in need of emergency treatment. The shortage of these medications is not only causing distress for patients but also increasing the burden on healthcare providers who are already stretched to the limit.

We understand that the situation is complex and multifaceted, involving supply chain disruptions, manufacturing challenges, and distribution issues. However, it is our belief that there are steps that can be taken to alleviate this situation and protect the patients who rely on these medications.

We recommend the following actions:

1. Increase investment in domestic drug manufacturing and supply chains to reduce dependence on imports.
2. Implement a national strategy for managing drug shortages, including early identification and response to shortages.
3. Encourage alternative sources of supply and diversification of procurement strategies.
4. Provide financial support to healthcare providers to mitigate the impact of drug shortages.
5. Enhance communication between various stakeholders to ensure timely information sharing.

We urge you to take these actions seriously and address this critical issue as a matter of urgency. The healthcare system in Canada relies on the availability of necessary medications to provide quality care to patients. We stand ready to work with you and your team to find solutions to this problem.

Sincerely,

[Your Name]
[Your Position]
[Your Organization]
Protecting and supporting Canada’s health-care providers during COVID-19
https://policybase.cma.ca/link/policy14260

POLICY TYPE
Parliamentary submission

DATE
2020-03-23

TOPICS
Physician practice, compensation, forms
Health systems, system funding and performance
Health human resources

Documents

March 20, 2020

Dr. Mike Toews
Chair, College of Physicians

Dr. Deanna Zazulak
President, College of Physicians

Dear colleagues,

We are writing to express our deep concern about the rapidly evolving COVID-19 pandemic and its potential impact on the health and well-being of Canadians. As healthcare providers, we are committed to ensuring that our patients receive the care they need during this unprecedented crisis.

We understand that the pandemic has put a tremendous strain on our healthcare system and its workforce. We recognize the challenges that healthcare providers are facing, including shortages of personal protective equipment, increased workload, and the emotional toll of caring for patients with COVID-19.

As you know, the Canadian Medical Association (CMA) has been working closely with federal, provincial, and territorial governments to ensure that healthcare providers have the support they need to respond to the pandemic. We have been advocating for increased funding for public health systems and for measures to protect the health and safety of healthcare providers.

In light of these challenges, we are calling for immediate action to protect and support healthcare providers. This includes:

- Increased funding for public health systems to support the deployment of resources and personnel.
- Access to personal protective equipment for all healthcare providers.
- Support for mental health and well-being programs for healthcare providers.
- Ensuring that healthcare providers have the necessary resources to respond to the pandemic, including testing capacity and vaccine distribution.

We understand that these are unprecedented times, and we are committed to working with all stakeholders to ensure that healthcare providers have the support they need to respond to the pandemic.

We appreciate your continued dedication and hard work in this challenging time. We are confident that together, we can overcome this crisis and emerge stronger.

Sincerely,

Dr. Mike Toews
Chair, College of Physicians

Dr. Deanna Zazulak
President, College of Physicians
CMA POLICY

Flexibility in Medical Training

[Update 2009]

The Canadian Medical Association (CMA) recognizes the importance of flexibility in medical training. Flexibility allows medical students and residents to better integrate their education with the diverse needs of the patients they serve. It also allows for a more efficient use of resources, particularly during times of fiscal stress. The CMA supports initiatives that promote flexibility in medical training, such as offering electives in a wide range of specialties, allowing for a more rapid completion of training, and encouraging the development of interdisciplinary approaches to patient care.

This policy also recognizes the importance of ensuring that medical training is not only flexible but also of high quality. The CMA encourages medical schools and training programs to maintain high standards of education and to ensure that medical students and residents receive the best possible training.

Definitions

- Medical school: An institution that offers a program leading to the degree of Doctor of Medicine (MD).
- Residency program: A program of supervised clinical training following graduation from medical school and leading to the award of a postgraduate degree in medicine.
- Elective course: A course that is not part of the required curriculum, but is offered as an optional course to medical students.
- Interdisciplinary approach: An approach to patient care that involves the collaboration of physicians from different specialties.

The CMA supports the development and implementation of policies and initiatives that promote flexibility in medical training, and encourages medical schools and training programs to consider the benefits of flexibility in their planning and decision-making processes.

This policy was updated in 2009 to reflect the latest developments in medical education and training.
Authorizing Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy11514

POLICY TYPE
Policy document
LAST REVIEWED
2020-02-29
DATE
2015-02-28
TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on reducing youth access and appeal of vaping products
https://policybase.cma.ca/link/policy14078

POLICY TYPE Response to consultation
DATE 2019-05-24
TOPICS Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Standing Committee on Health’s study on violence faced by healthcare workers

https://policybase.cma.ca/link/policy14052

POLICY TYPE
Parliamentary submission

DATE
2019-05-14

TOPICS
Health care and patient safety
Ethics and medical professionalism
Health human resources
Physician practice, compensation, forms
Scopes of practice

https://policybase.cma.ca/link/policyl237

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2002-01-22
TOPICS  Health human resources

Documents
Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy10045

POLICY TYPE  
Policy document

LAST REVIEWED  
2019-03-03

DATE  
2010-12-04

TOPICS  
Pharmaceuticals, prescribing, cannabis, drugs

Documents

Cannabis for Medical Purposes

CMA POLICY

Cannabis for Medical Purposes

Cannabis for Medical Purposes

The Canadian Medical Association (CMA), long ago acknowledged the virtue in requiring individuals suffering from terminal illnesses to be able to access cannabis for medical purposes provided they received a medical certificate from a qualified physician. As it continues to receive requests for information and moral support from individuals in this situation, and the media report on the efforts of physicians to facilitate such access, the CMA rights to its members to make such efforts. The CMA also recognizes that more information is available on the medicinal use of cannabis.

The CMA endorses the following recommendations:

1. Increase support for the advancement of scientific knowledge about the medical use of cannabis. 
2. Increase support for the education of health care professionals in the assessment and management of patients. 
3. Increase support for the development of guidelines for the use of cannabis.

The CMA further notes that it acknowledges the potential for medical cannabis to contribute to the medical care of some patients, but it is not a cure for cancer or other diseases. It recognizes the potential dangers of cannabis and the need for careful monitoring and control. It supports the development of guidelines for the use of cannabis. It further notes that it acknowledges the potential for medical cannabis to contribute to the medical care of some patients, but it is not a cure for cancer or other diseases. It recognizes the potential dangers of cannabis and the need for careful monitoring and control. It supports the development of guidelines for the use of cannabis.

The CMA further notes that it acknowledges the potential for medical cannabis to contribute to the medical care of some patients, but it is not a cure for cancer or other diseases. It recognizes the potential dangers of cannabis and the need for careful monitoring and control. It supports the development of guidelines for the use of cannabis.

The CMA further notes that it acknowledges the potential for medical cannabis to contribute to the medical care of some patients, but it is not a cure for cancer or other diseases. It recognizes the potential dangers of cannabis and the need for careful monitoring and control. It supports the development of guidelines for the use of cannabis.

The CMA further notes that it acknowledges the potential for medical cannabis to contribute to the medical care of some patients, but it is not a cure for cancer or other diseases. It recognizes the potential dangers of cannabis and the need for careful monitoring and control. It supports the development of guidelines for the use of cannabis.

The CMA further notes that it acknowledges the potential for medical cannabis to contribute to the medical care of some patients, but it is not a cure for cancer or other diseases. It recognizes the potential dangers of cannabis and the need for careful monitoring and control. It supports the development of guidelines for the use of cannabis.

The CMA further notes that it acknowledges the potential for medical cannabis to contribute to the medical care of some patients, but it is not a cure for cancer or other diseases. It recognizes the potential dangers of cannabis and the need for careful monitoring and control. It supports the development of guidelines for the use of cannabis.
MEDICATION USE AND SENIORS

(UPDATE 2017)

Policy Document

The Canadian Medical Association (CMA) recommends that the use of medication for the treatment of chronic conditions in elderly patients be carefully monitored, and that appropriate adjustments be made to the medication regimen. This is particularly important for those patients who are taking multiple medications, as the risk of adverse drug interactions increases. The CMA recommends that physicians regularly review the medication profiles of their elderly patients and make necessary adjustments to prevent adverse effects.

Some specific recommendations include:

- Conducting comprehensive medication reviews with patients
- Identifying unnecessary medications and discontinuing them
- Monitoring for adverse drug reactions
- Educating patients on medication management

The CMA also recommends that pharmacists be involved in the medication review process to provide additional expertise. This collaboration can help ensure that the medication regimen is optimized for the patient's health needs.

The CMA Policybase - Canadian Medical Association
Vision for e-Prescribing: a joint statement by the Canadian Medical Association and the Canadian Pharmacists Association

https://policybase.cma.ca/link/policy10670

POLICY TYPE: Policy document
LAST REVIEWED: 2019-03-03
DATE: 2012-12-08
TOPICS: Health information and e-health, Pharmaceuticals, prescribing, cannabis, drugs

Documents
MANAGEMENT OF PHYSICIAN FATIGUE

Policy

Management of physician fatigue is addressed in the following Canadian Medical Association (CMA) policy:

Management of physician fatigue

http://policybase.cma.ca/link/policy11127

POLICY TYPE

Policy document

LAST REVIEWED

2019-03-03

DATE

2014-05-24

TOPICS

Health human resources

Documents